Subscribe
shutterstock_1049695967_piotr_swat
Piotr Swat / Shutterstock.com
24 May 2019Big Pharma

CMA accuses 4 pharma companies of anti-competitive conduct

Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service (NHS), according to objections filed by the UK Competition and Markets Authority (CMA).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
CMA alleges collusion allowed 1,800% hike in Aspen drug pricing
9 October 2019   African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority.
Biotechnology
CMA reveals antitrust investigation into Essential Pharma over bipolar drug
30 November 2020   The UK Competition and Markets Authority is investigating Essential Pharma over suspicions that the pharmaceutical company contravened competition law by proposing to withdraw the supply of Priadel, a lithium-based medication for bipolar disease.
Europe
CMA fines drugmakers £260m for 10,000% price hike
15 July 2021   The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
CMA alleges collusion allowed 1,800% hike in Aspen drug pricing
9 October 2019   African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority.
Biotechnology
CMA reveals antitrust investigation into Essential Pharma over bipolar drug
30 November 2020   The UK Competition and Markets Authority is investigating Essential Pharma over suspicions that the pharmaceutical company contravened competition law by proposing to withdraw the supply of Priadel, a lithium-based medication for bipolar disease.
Europe
CMA fines drugmakers £260m for 10,000% price hike
15 July 2021   The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.

More on this story

Big Pharma
CMA alleges collusion allowed 1,800% hike in Aspen drug pricing
9 October 2019   African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority.
Biotechnology
CMA reveals antitrust investigation into Essential Pharma over bipolar drug
30 November 2020   The UK Competition and Markets Authority is investigating Essential Pharma over suspicions that the pharmaceutical company contravened competition law by proposing to withdraw the supply of Priadel, a lithium-based medication for bipolar disease.
Europe
CMA fines drugmakers £260m for 10,000% price hike
15 July 2021   The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent